Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Leann A. Lovejoy; Craig D. Shriver; Svasti Haricharan; Rachel E. Ellsworth

doi:10.3390/ijerph20042903

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Leann A. Lovejoy, Craig D. Shriver, Svasti Haricharan, Rachel E. Ellsworth^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.

Original language	English
Article number	2903
Journal	International Journal of Environmental Research and Public Health
Volume	20
Issue number	4
DOIs	https://doi.org/10.3390/ijerph20042903
State	Published - Feb 2023
Externally published	Yes

Keywords

Black
biological
breast cancer
disparity
hormone receptor positive/HER2 negative
treatment

Access to Document

10.3390/ijerph20042903

Cite this

@article{4652287643064137af5589328edb83b3,

title = "Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer",

abstract = "Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.",

keywords = "Black, biological, breast cancer, disparity, hormone receptor positive/HER2 negative, treatment",

author = "Lovejoy, {Leann A.} and Shriver, {Craig D.} and Svasti Haricharan and Ellsworth, {Rachel E.}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = feb,

doi = "10.3390/ijerph20042903",

language = "English",

volume = "20",

journal = "International Journal of Environmental Research and Public Health",

issn = "1661-7827",

number = "4",

}

TY - JOUR

T1 - Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

AU - Lovejoy, Leann A.

AU - Shriver, Craig D.

AU - Haricharan, Svasti

AU - Ellsworth, Rachel E.

PY - 2023/2

Y1 - 2023/2

N2 - Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.

AB - Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.

KW - Black

KW - biological

KW - breast cancer

KW - disparity

KW - hormone receptor positive/HER2 negative

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85148963912&partnerID=8YFLogxK

U2 - 10.3390/ijerph20042903

DO - 10.3390/ijerph20042903

M3 - Review article

C2 - 36833598

AN - SCOPUS:85148963912

SN - 1661-7827

VL - 20

JO - International Journal of Environmental Research and Public Health

JF - International Journal of Environmental Research and Public Health

IS - 4

M1 - 2903

ER -

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this